PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30171779-1	2018	AIM: We report on two Phase 1, open-label, single-arm studies assessing the effect of osimertinib on simvastatin (CYP3A substrate) and rosuvastatin (breast cancer resistance protein substrate [BCRP] substrate) exposure in patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer who have progressed after treatment with an EGFR tyrosine kinase inhibitor, to determine, upon coadministration, whether osimertinib could affect the exposure of these agents.	osimertinib	86-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-119	
35359868-1	2022	The aim of this study was to 1) investigate the effects of 27 CYP3A4 variants on the metabolism of osimertinib and 2) study the interactions between osimertinib and others as well as the underlying mechanism.	osimertinib	99-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68	
35359868-1	2022	The aim of this study was to 1) investigate the effects of 27 CYP3A4 variants on the metabolism of osimertinib and 2) study the interactions between osimertinib and others as well as the underlying mechanism.	osimertinib	149-160	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68	
35359868-4	2022	The results demonstrated that the relative clearance rates of CYP3A4.19, 10, 18, 5, 16, 14, 11, 2, 13, 12, 7, 8, and 17 in catalyzing osimertinib were significantly reduced to a minimum of 25.68% compared to CYP3A4.1, while those of CYP3A4.29, 32, 33, 28, 15, 34, and 3 were obviously enhanced, ranging from 114.14% to 284.52%.	osimertinib	134-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68	
35359868-4	2022	The results demonstrated that the relative clearance rates of CYP3A4.19, 10, 18, 5, 16, 14, 11, 2, 13, 12, 7, 8, and 17 in catalyzing osimertinib were significantly reduced to a minimum of 25.68% compared to CYP3A4.1, while those of CYP3A4.29, 32, 33, 28, 15, 34, and 3 were obviously enhanced, ranging from 114.14% to 284.52%.	osimertinib	134-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	233-239	
35005653-4	2022	Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary.	osimertinib	38-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111